Alternatively, tumor-associated antigens (TAAs) have served as a target for CTL immunotherapy as DNA vaccines have a therapeutic effect on established tumors through activation of a CD8 T cell-dependent pathway (35,36). Here, CD8A is linked to neoplasm.